Allakos Inc.
ALLK Real Time Price USDRecent trades of ALLK by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Purchase $1,001 - $15,000 | Jun. 16, 2022 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALLK's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anti-siglec-7 antibodies having reduced effector function Feb. 27, 2024
-
Patent Title: Anti-siglec-7 antibodies for the treatment of cancer Oct. 03, 2023
-
Patent Title: Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis Dec. 21, 2021
-
Patent Title: Methods and compositions for treating fibrotic diseases Sep. 15, 2020
-
Patent Title: Methods and compositions for treating siglec-8 associated diseases Jan. 22, 2019
-
Patent Title: Anti-siglec-8 antibodies and methods of use thereof Jan. 17, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ALLK in WallStreetBets Daily Discussion
Recent insights relating to ALLK
Recent picks made for ALLK stock on CNBC
ETFs with the largest estimated holdings in ALLK
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALLK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.